Bortezomib based therapies for myeloma

Bookmark and Share
Published: 2 Jul 2009
Views: 15013
Rating:
Save
Dr Paul Richardson - Hematologic Oncology Dept, Dana-Farber Cancer Institute
Dr Paul Richardson, Hematologic Oncology Dept, Dana-Farber Cancer Institute, speaking at ASCO 2009 about Bortezomib based therapies in relapsed and refractory myeloma. Tanespimycin with bortezomib (some neuroprotection found). HSP-90 inhibtion is an important therapeutic target. Also covers his highlights from the conference. Also lenalidomide with bortezomib and dexamethasone (RVD platform)